Aroa Biosurgery (ARX) 주식 개요
아로아 바이오서저리는 미국 및 전 세계에서 세포외기질(ECM) 기술을 사용하여 상처 및 연조직 복구용 의료 기기를 개발, 제조 및 판매하는 회사입니다. 자세히 보기
ARX Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aroa Biosurgery Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | AU$0.57 |
| 52주 최고가 | AU$0.80 |
| 52주 최저가 | AU$0.49 |
| 베타 | 0.85 |
| 1개월 변동 | -10.85% |
| 3개월 변동 | 6.48% |
| 1년 변동 | 0% |
| 3년 변동 | -35.75% |
| 5년 변동 | -53.82% |
| IPO 이후 변동 | -57.41% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 06
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.
내러티브 업데이트 • Jun 22
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.내러티브 업데이트 • Jun 05
ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.Recent updates
내러티브 업데이트 • Jul 06
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.내러티브 업데이트 • Jun 22
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.내러티브 업데이트 • Jun 05
ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.내러티브 업데이트 • May 03
ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
새로운 내러티브 • Apr 08
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Mar 24
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?분석 기사 • Nov 28
Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
새로운 내러티브 • Apr 26
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.분석 기사 • Apr 07
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...분석 기사 • Mar 24
Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Feb 15
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Dec 04
Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...분석 기사 • Nov 27
The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...분석 기사 • Nov 13
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...분석 기사 • Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...분석 기사 • Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...분석 기사 • Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...분석 기사 • Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...분석 기사 • May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...주주 수익률
| ARX | AU Biotechs | AU 시장 | |
|---|---|---|---|
| 7D | -3.4% | 7.2% | 0.2% |
| 1Y | 0% | -45.8% | 2.2% |
수익률 대 산업: ARX은 지난 1년 동안 -45.8%의 수익을 기록한 Australian Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: ARX은 지난 1년 동안 2.2%를 기록한 Australian 시장보다 저조한 성과를 냈습니다.
주가 변동성
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 4.0% |
안정적인 주가: ARX는 지난 3개월 동안 Australian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ARX의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroa.com |
아로아 바이오서저리는 세포외기질(ECM) 기술을 이용한 상처 및 연조직 복구용 의료기기를 개발, 제조 및 판매하는 회사로 미국 및 전 세계에 판매하고 있습니다. 주요 제품으로는 급성 및 만성 상처 치료를 위한 Endoform Natural 및 Endoform 항균성 복원 바이오스캐폴드, 연조직 복구, 보강 및 복합 상처를 위한 엔지니어링 ECM인 Myriad Matrix, 연조직 복구 및 복합 상처를 위한 모셀화(분말) 형태의 Myriad Matrix인 Myriad Morcells가 있습니다; 생물학적으로 중요한 ECM 단백질을 대량으로 공급하여 치유를 시작하고 유지하는 데 도움을 주는 '미리어드 모셀스 파인', 복잡한 상처의 기능적 조직 재생을 위한 세포 및 조직 복합 제품인 '심포니' 등이 있습니다. 또한 북미와 유럽에서 복벽 재건, 탈장 복구 및 유방 재건용 제품을 개발하고 있습니다.
Aroa Biosurgery Limited 기초 지표 요약
| ARX 기초 통계 | |
|---|---|
| 시가총액 | AU$198.89m |
| 순이익 (TTM) | AU$3.83m |
| 매출 (TTM) | AU$85.05m |
51.9x
주가수익비율(P/E)2.3x
주가매출비율(P/S)ARX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ARX 손익계산서 (TTM) | |
|---|---|
| 매출 | NZ$103.85m |
| 매출원가 | NZ$15.03m |
| 총이익 | NZ$88.83m |
| 기타 비용 | NZ$84.15m |
| 순이익 | NZ$4.68m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.014 |
| 총이익률 | 85.53% |
| 순이익률 | 4.50% |
| 부채/자본 비율 | 0% |
ARX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/07 18:15 |
| 종가 | 2026/07/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Aroa Biosurgery Limited는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |